Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)
Recruiting · NCT06096246 · Interventional (participants receive a specific treatment) · Lead sponsor: Barts & The London NHS Trust
View the official record on ClinicalTrials.gov →Interventions studied
DC CardioversionFemoral sheath insertionImplantable loop recorderPulmonary vein isolation
What this trial is about
The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.
Who can take part
Age range
18 Years to 85 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Ability to give informed consent
- Age 18-85 years
- Persistent AF (atrial fibrillation lasting \> 7days) of total continuous duration \<2 years as documented in medical notes.
- Patients being considered for cardioversion.
Exclusion criteria
- Creatinine clearance (eGFR) \< 30mls/min
- Contraindication or unable to take anticoagulation
- Uncontrolled hypertension
- Contraindication for catheter ablation
- BMI \> 40
- Patients in Persistent AF who have had more than one previous cardioversion.
- Established diagnosis of Hypertrophic cardiomyopathy
Where it is running
1 location listed.
- Barts Heart Centre - London, United Kingdom